02803cam a2200265 a 4500003000900000005001700009008004100026040002800067041000800095100002500103245017500128246016100303260004400464300003200508502009000540520170400630530002202334653001802356653001902374653001402393700003002407700003502437700003202472856003302504EG-GiCUC20250223032842.0211104s2021    ua d   f m    000 0 eng d  aEG-GiCUCbengcEG-GiCUC0 aeng0 aMohammed Said Hassan10aRituximab versus azathioprine therapy in neuromyelitis optica spectrum disorder patients / cMohammed Said Hassan ; Supervised Sherif Hamdy , Nevin Moheildin , Ahmed Nemr15aعقار ريتوكسيماب مقابل عقار الأزاثيوبرين فى مرضى التهاب النخاع العصبى الطيفى البصرى   aCairo : bMohammed Said Hassan , c2021  a164 P . : bcharts ; c25cm  aThesis (Ph.D.) - Cairo University - Faculty of Medicine - Department of Neuro Surgery  aBackground: Neuromyelitis optica (NMO) is an autoimmune inflammatory disease of the central nervous system characterized by severe attacks of optic neuritis and longitudinally extensive transverse myelitis. Recently, the demonstration of a pathogenic role for the anti{u2013}aquaporin 4 (AQP4) antibody in NMO has marked a major advance in the understanding o the disease Aim of work: The aim of this study was to report the results of rituximab treatment in NMO spectrum disorders (NMOSDs) Patients and Methods: This was a retrospective observational study conducted on 74 Egyptian patients with NMOSDs. The patients{u2018} data were recruited from patient records in multiple sclerosis (MS) clinics, Neurology Departments, El- Maady Military Hospital (records from 2005) and Cairo University hospitals (Kasr Al-Ainy MS Clinic) (records from 2013) including their full medical history, general and neurological examination, MRI brain and spinal cord results, and laboratory investigation including: immune assays and AQP- 4antibody testing as per MS and MS mimics sheet of Kasr Al-Ainy MS clinic.Results: The study included 74 Patients with NMOSD according to criteria of Wagnerchuck 2015. Both sero-positive and sero-negative anti-aquaporin-4 (AQP-4) antibodies patients were included in the study. The patients were divided into three groups: group 1 (RTX group) included 25 patient; group 2 (AZA group) included 32 patients, and group 3 (Switchers) included 17 patients. Conclusion: our findings suggest that RTX is more effective and safe than AZA in NMO-SD patients. Further studies with larger sample sizes and longer duration of follow-up are reqired to confirm these findings in our country  aIssued also as CD 4aAzathioprine  4aNeuromyelitis  4aRituximab0 aAhmed Nemr , eSupervisor0 aNevin Moheildin , eSupervisor0 aSherif Hamdy , eSupervisor  uhttp://172.23.153.220/th.pdf